APO RESEARCH · REPORT
Anti-Venom
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
Product & engineering
Understand the product.
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
Selected research
Industry Research
Anti-Venom Industry Research Report 2026
Market perspective
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
Report Scope
Read the full market overview
This report quantifies the global Anti-Venom market in terms of revenue (US$ million) and, where applicable, sales volume (K Vials), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Vials) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Anti-Venom Market by Company
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Anti-Venom Segment by Type
Polyvalent Anti-Venom
Monovalent Anti-Venom
Anti-Venom Segment by Application
Non-profit Institutions
Hospitals and Clinic
Anti-Venom Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Venom market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Venom and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Venom.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Anti-Venom manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Anti-Venom by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Anti-Venom in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Polyvalent Anti-Venom
- Monovalent Anti-Venom
Applications
- Non-profit Institutions
- Hospitals and Clinic
Companies covered
- CSL
- Merck
- BTG
- Pfizer
- Haffkine Bio-Pharmaceutical
- Rare Disease Therapeutics
- Flynn Pharma
- Vins Bioproducts
- Bharat Serums and Vaccines
- Serum Biotech
- MicroPharm
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Anti-Venom Market Size (2021-2032)
- 2.2.2 Global Anti-Venom Sales (2021-2032)
- 2.2.3 Global Anti-Venom Market Average Price (2021-2032)
- 2.3 Anti-Venom by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Polyvalent Anti-Venom
- 2.3.3 Monovalent Anti-Venom
- 2.4 Anti-Venom by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Non-profit Institutions
- 2.4.3 Hospitals and Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Anti-Venom Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Anti-Venom Sales (K Vials) of Manufacturers (2021-2026)
- 3.3 Global Anti-Venom Revenue of Manufacturers (2021-2026)
- 3.4 Global Anti-Venom Average Price by Manufacturers (2021-2026)
- 3.5 Global Anti-Venom Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Anti-Venom, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Anti-Venom, Product Type & Application
- 3.8 Global Manufacturers of Anti-Venom, Established Date
- 3.9 Global Anti-Venom Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CSL
- 4.1.1 CSL Company Information
- 4.1.2 CSL Business Overview
- 4.1.3 CSL Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CSL Anti-Venom Product Portfolio
- 4.1.5 CSL Recent Developments
- 4.2 Merck
- 4.2.1 Merck Company Information
- 4.2.2 Merck Business Overview
- 4.2.3 Merck Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck Anti-Venom Product Portfolio
- 4.2.5 Merck Recent Developments
- 4.3 BTG
- 4.3.1 BTG Company Information
- 4.3.2 BTG Business Overview
- 4.3.3 BTG Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 BTG Anti-Venom Product Portfolio
- 4.3.5 BTG Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Anti-Venom Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 Haffkine Bio-Pharmaceutical
- 4.5.1 Haffkine Bio-Pharmaceutical Company Information
- 4.5.2 Haffkine Bio-Pharmaceutical Business Overview
- 4.5.3 Haffkine Bio-Pharmaceutical Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Haffkine Bio-Pharmaceutical Anti-Venom Product Portfolio
- 4.5.5 Haffkine Bio-Pharmaceutical Recent Developments
- 4.6 Rare Disease Therapeutics
- 4.6.1 Rare Disease Therapeutics Company Information
- 4.6.2 Rare Disease Therapeutics Business Overview
- 4.6.3 Rare Disease Therapeutics Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Rare Disease Therapeutics Anti-Venom Product Portfolio
- 4.6.5 Rare Disease Therapeutics Recent Developments
- 4.7 Flynn Pharma
- 4.7.1 Flynn Pharma Company Information
- 4.7.2 Flynn Pharma Business Overview
- 4.7.3 Flynn Pharma Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Flynn Pharma Anti-Venom Product Portfolio
- 4.7.5 Flynn Pharma Recent Developments
- 4.8 Vins Bioproducts
- 4.8.1 Vins Bioproducts Company Information
- 4.8.2 Vins Bioproducts Business Overview
- 4.8.3 Vins Bioproducts Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Vins Bioproducts Anti-Venom Product Portfolio
- 4.8.5 Vins Bioproducts Recent Developments
- 4.9 Bharat Serums and Vaccines
- 4.9.1 Bharat Serums and Vaccines Company Information
- 4.9.2 Bharat Serums and Vaccines Business Overview
- 4.9.3 Bharat Serums and Vaccines Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Bharat Serums and Vaccines Anti-Venom Product Portfolio
- 4.9.5 Bharat Serums and Vaccines Recent Developments
- 4.10 Serum Biotech
- 4.10.1 Serum Biotech Company Information
- 4.10.2 Serum Biotech Business Overview
- 4.10.3 Serum Biotech Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Serum Biotech Anti-Venom Product Portfolio
- 4.10.5 Serum Biotech Recent Developments
- 4.11 MicroPharm
- 4.11.1 MicroPharm Company Information
- 4.11.2 MicroPharm Business Overview
- 4.11.3 MicroPharm Anti-Venom Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 MicroPharm Anti-Venom Product Portfolio
- 4.11.5 MicroPharm Recent Developments
5 Global Anti-Venom Market Scenario by Region
- 5.1 Global Anti-Venom Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Anti-Venom Sales by Region: 2021-2032
- 5.2.1 Global Anti-Venom Sales by Region: 2021-2026
- 5.2.2 Global Anti-Venom Sales by Region: 2027-2032
- 5.3 Global Anti-Venom Revenue by Region: 2021-2032
- 5.3.1 Global Anti-Venom Revenue by Region: 2021-2026
- 5.3.2 Global Anti-Venom Revenue by Region: 2027-2032
- 5.4 North America Anti-Venom Market Facts & Figures by Country
- 5.4.1 North America Anti-Venom Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Anti-Venom Sales by Country (2021-2032)
- 5.4.3 North America Anti-Venom Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Anti-Venom Market Facts & Figures by Country
- 5.5.1 Europe Anti-Venom Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Anti-Venom Sales by Country (2021-2032)
- 5.5.3 Europe Anti-Venom Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Anti-Venom Market Facts & Figures by Country
- 5.6.1 Asia Pacific Anti-Venom Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Anti-Venom Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Anti-Venom Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Anti-Venom Market Facts & Figures by Country
- 5.7.1 South America Anti-Venom Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Anti-Venom Sales by Country (2021-2032)
- 5.7.3 South America Anti-Venom Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Anti-Venom Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Anti-Venom Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Anti-Venom Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Anti-Venom Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Anti-Venom Sales by Type (2021-2032)
- 6.1.1 Global Anti-Venom Sales by Type (2021-2032) & (K Vials)
- 6.1.2 Global Anti-Venom Sales Market Share by Type (2021-2032)
- 6.2 Global Anti-Venom Revenue by Type (2021-2032)
- 6.2.1 Global Anti-Venom Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Anti-Venom Revenue Market Share by Type (2021-2032)
- 6.3 Global Anti-Venom Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Anti-Venom Sales by Application (2021-2032)
- 7.1.1 Global Anti-Venom Sales by Application (2021-2032) & (K Vials)
- 7.1.2 Global Anti-Venom Sales Market Share by Application (2021-2032)
- 7.2 Global Anti-Venom Revenue by Application (2021-2032)
- 7.2.1 Global Anti-Venom Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Anti-Venom Revenue Market Share by Application (2021-2032)
- 7.3 Global Anti-Venom Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Anti-Venom Value Chain Analysis
- 8.1.1 Anti-Venom Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Anti-Venom Production Mode & Process
- 8.2 Anti-Venom Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Anti-Venom Distributors
- 8.2.3 Anti-Venom Customers
9 Global Anti-Venom Analyzing Market Dynamics
- 9.1 Anti-Venom Industry Trends
- 9.2 Anti-Venom Industry Drivers
- 9.3 Anti-Venom Industry Opportunities and Challenges
- 9.4 Anti-Venom Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst